default author photo

Audrey Mauguen

Memorial Sloan Kettering Cancer Center - Department of Epidemiology and Biostatistics

New York, NY

United States

SCHOLARLY PAPERS

3

DOWNLOADS

156

TOTAL CITATIONS

1

Scholarly Papers (3)

1.

Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer

Number of pages: 26 Posted: 26 Nov 2025
Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Please see PDF for full list of authors & affiliations
Downloads 84 (867,774)

Abstract:

Loading...

GLP-1RA, thyroid cancer, structural recurrence

2.

An RNA-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment Resistant Malignancies

Number of pages: 55 Posted: 28 Mar 2022
Columbia University - Irving Medical Center, Memorial Sloan Kettering Cancer Center, Columbia University - Irving Medical Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Memorial Sloan Kettering Cancer Center, Columbia University - Department of Systems Biology, Columbia University - Herbert Irving Comprehensive Cancer Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Department of Medicine, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Department of Medicine, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Cambridge, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University - Irving Medical Center, Columbia University, Columbia University - Irving Medical Center, Columbia University - Department of Systems Biology, DarwinHealth, Inc., Memorial Sloan Kettering Cancer Center and Columbia University Irving Medical Center - Department of Systems Biology
Downloads 46 (1,121,190)
Citation 1

Abstract:

Loading...

precision cancer medicine, computational inference, drug prediction, patient derived xenograft, high throughput drug screen, protein activity, regulatory network, systems biology, VIPER, OncoTarget, OncoTreat, PLATESeq, breast cancer, sarcoma, meningioma, colon cancer, pancreatic cancer

3.

Concordance of Efficacy and Safety in Phase Ib/Ii and Phase Iii Solid Tumour Treatment Trials

Number of pages: 22 Posted: 26 Jul 2025
McGill University, McGill University, McGill University, McGill University, McGill University, Memorial Sloan Kettering Cancer Center - Department of Epidemiology and Biostatistics and McGill University - BioMedical Ethics Unit
Downloads 26 (1,385,945)

Abstract:

Loading...

Clinical Trials, Phase II, Oncology, Ethics, drug development, Regulatory Approval, Risk, Meta-Research